Efficacy, Safety, and Adequacy of EUS-guided Liver Biopsy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04055870

Enrollment

Registered

2019-08-14

Start date

2017-08-21

Completion date

2020-10-30

Last updated

2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatic, Liver Diseases

Brief summary

The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical Center (MDMC).

Detailed description

The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical Center (MDMC). This is a clinical quality improvement (CQI) initiative to evaluate outcomes within our institution. The data collected will be used to inform new innovative ways to improve EUS-guided liver biopsy with an ultimate goal of improving the quality of patient care. The clinical outcomes of this patient population have not been previously systematically reviewed in MDMC. Currently, the procedure in not being performed routinely at Methodist Dallas Medical Center (MDMC). However, with new technical and physician expertise, this option is now available at our institution. PI will evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients requiring histologic examination of their liver at MDMC.

Interventions

PROCEDUREEUS-guided liver biopsy at MDMC

Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age 18 years or older * Undergone EUS-guided liver biopsy at MDMC

Exclusion criteria

* Below 18 years of age * Did not undergo EUS-guided liver biopsy at MDMC

Design outcomes

Primary

Measure	Time frame	Description
Length of core biopsy	9/1/2017 and 9/1/2019	—
Number of portal tracts	9/1/2017 and 9/1/2019	—
Diagnostic yield	9/1/2017 and 9/1/2019	We will define an adequate specimen as one containing ≥11 portal tracts or measuring ≥20 mm cumulative core length.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026